Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872573 | 0.82 | FBP1 (0.49) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3379193 | 0.82 | LMNA (0.52) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL30832672 | 0.82 | ALDH1A1 (0.56) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL12312090 | 0.82 | ALDH1A1 (0.56) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL15156883 | 0.79 | FBP1 (0.49) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL7473254 | 0.79 | FBP1 (0.46) | HPGDFBP1KDM4EPOLBALDH1A1 | |
| SCHEMBL15283772 | 0.79 | KDM4E (0.44) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL7419084 | 0.78 | KDM4E (0.46) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL11995606 | 0.77 | ALDH1A1 (0.50) | FBP1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10179500 | 0.77 | FBP1 (0.47) | FBP1KDM4EPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| US-4783467-A | Tetrahydroimidazoquinazolinone inotropic agents | PFIZER INC. (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0205280-A2 | Tetrahydroimidazoquinazolinone cardiac stimulants | Pfizer Limited (GB) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | HPGD 415/4885FBP1 2644/4885KDM4E 3146/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | HPGD 4354/4885FBP1 3662/4885KDM4E 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.